Cologuard Plus is only noninvasive test to be evaluated head-to-head against an independent fecal immunochemical test, which it significantly outperformed
20,000-participant BLUE-C study included.
<p>For World Cancer Day, February 4th, NCCN, ACS CAN, and NMQF are announcing three key areas of policy focus as part of the Alliance for Cancer Care Equity (ACCE) joint collaboration, including advancing diversity in clinical trials, improving cancer screening and early detection, and increasing access to patient navigation. </p>
/PRNewswire/ For World Cancer Day, the National Comprehensive Cancer Network® (NCCN®), American Cancer Society Cancer Action Network (ACS CAN), and the.
For World Cancer Day, February 4th, NCCN, ACS CAN, and NMQF are announcing three key areas of policy focus as part of the Alliance for Cancer Care Equity (ACCE)